Patients with advanced non-small cell lung cancer live longer if they undergo comprehensive genomic testing of their tumors before starting treatment, allowing a broad range of genetic alterations to be identified. Researchers reached this conclusion after analyzing data from more than 35,000 patients in the United States.

The study findings were published in the November 2026 issue of the Journal of the National Comprehensive Cancer Network. The researchers examined data on patients treated at public and private cancer centers in the United States between 2016 and 2022.

Comprehensive genomic testing allows dozens or even hundreds of tumor genes to be tested simultaneously. In contrast, limited molecular genetic testing covers only one or two biomarkers that may indicate the potential effectiveness of certain drugs.

According to the analysis, patients who underwent comprehensive testing before starting first-line therapy lived an average of two months longer. They also showed a slight improvement in progression-free survival.

One possible explanation was the more frequent use of targeted therapy—treatment directed at specific molecular targets in tumor cells. Among patients who underwent comprehensive genomic testing, 19% received these drugs, compared with 16% in the limited-testing group.

“Our findings and previous studies suggest that comprehensive genomic testing should become the standard for patients with advanced lung cancer and ideally be performed before first-line therapy begins,” said study co-author Ravi B. Parikh of Emory University School of Medicine and Winship Cancer Institute.

When selecting treatment, physicians may consider biomarkers such as EGFR, ALK, ROS1, KRAS G12C, MET, RET, and BRAF. Identifying the corresponding genetic alterations helps determine whether a patient may benefit from specific targeted drugs that act on tumor growth mechanisms and, in some cases, are better tolerated than other treatments.

Guidelines from the U.S. National Comprehensive Cancer Network (NCCN) already recommend comprehensive genomic testing for advanced and metastatic non-small cell lung cancer.